Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06FPF
|
|||
| Former ID |
DIB015064
|
|||
| Drug Name |
Valortim
|
|||
| Synonyms |
Anthrax antibody, Medarex; MDX-1303; Anthrax antibody, Medarex/PharmAthene; Anti-B anthracis, Bristol Myers Squibb/PharmAthene; Anti-B anthracis PA (anthrax), Medarex/BMS/PharmAthene
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 1 | [1] | |
| Company |
Pharmathene
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Protective antigen (Bact pagA) | Target Info | . | [2] |
| Pathway Interaction Database | Cellular roles of Anthrax toxin | |||
| Reactome | Uptake and function of anthrax toxins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01265745) Dose Escalation Study of Valortim (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers. Clin Vaccine Immunol. 2011 December; 18(12): 2136-2142. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.